Literature DB >> 9185731

Utility of preoperative radionuclide scanning for primary hyperparathyroidism.

C K Sinha1, R Hamaker, R C Hamaker, S B Freeman, R W Borrowdale, T C Huntley.   

Abstract

This study retrospectively reviews 60 cases of primary hyperparathyroidism, 21 of whom underwent technetium 99 sestamibi scanning and 10 of whom underwent thallium 201/technetium 99 pertechnetate scanning preoperatively. The sestamibi and thallium scans demonstrated an 89.5% and a 62.5% sensitivity rate for adenoma, respectively. Neither scan demonstrated hyperplastic glands well. Although the scans localized adenomatous glands to the correct side well, the ability to localize them more discretely was 68.4% and 62.5%, respectively. In cases of solitary adenoma the effect of an accurate preoperative scan on operative time for bilateral exploration was not significant, whereas the experience of the attending surgeon was significant. Also, the cost of the scans at our institution was greater than the cost of the time saved in performing even unilateral neck exploration. Thus preoperative radionuclide scanning is not cost-effective for the initial exploration of patients with primary hyperparathyroidism and is insufficiently sensitive to make routine unilateral neck exploration for adenoma consistently effective.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9185731     DOI: 10.1097/00005537-199706000-00009

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  1 in total

Review 1.  Clinical value of parathyroid scintigraphy with technetium-99m methoxyisobutylisonitrile: discrepancies in clinical data and a systematic metaanalysis of the literature.

Authors:  Martin Gotthardt; Bodo Lohmann; Thomas M Behr; Artur Bauhofer; Christiane Franzius; Meike L Schipper; Maria Wagner; Helmut Höffken; Helmut Sitter; Matthias Rothmund; Klaus Joseph; Christoph Nies
Journal:  World J Surg       Date:  2003-11-26       Impact factor: 3.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.